TP53 and acute myeloid leukemia: In addition, TP53 mutation has been associated with lower CR and CR with incomplete marrow recovery (CRi) rates in AML patients treated with venetoclax monotherapy, venetoclax plus chemotherapy or venetoclax in combination with decitabine as compared to wildtype TP53 patients in these settings [40,41].